Skip to main content
    I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.45
    -0.07 (-4.61%)

    Market Cap: $213.21M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inhibikase Therapeutics Inc (IKT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Inhibikase Therapeutics (IKT) to earn -$0.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $250000. Of 10 analysts, 9 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.

    RatingAnalystsShare
    Strong Buy110.0%
    Buy880.0%
    Hold110.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 60.0%.

    Fiscal year ending Dec 31, 2026
    -$0.40
    EPS consensus, revenue $250000
    Fiscal year ending Dec 31, 2027
    -$0.41
    EPS consensus, revenue $400000
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.40-$0.42 to -$0.382$250000N/A6
    Dec 31, 2027-$0.41-$0.45 to -$0.375$400000N/A5

    Quarterly Estimates

    The EPS consensus is -$0.11 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.11-$0.16 to -$0.0610$252500N/A10
    Mar 31, 2027-$0.11-$0.12 to -$0.092N/AN/A4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.44.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.40-$0.40-$0.40-$0.45-$0.44N/A
    Fiscal year ending Dec 31, 2027-$0.41-$0.42-$0.42-$0.43-$0.42N/A
    Quarter ending Mar 31, 2027-$0.11-$0.11-$0.11-$0.13-$0.13N/A

    Frequently Asked Questions About IKT

    What is the IKT stock forecast?

    Consensus analyst estimates put Inhibikase Therapeutics's EPS at -$0.40 for the fiscal year ending Dec 31, 2026, on revenue of $250000. The consensus rating from 10 analysts is Buy.

    How do analysts rate IKT stock?

    Of 10 analysts covering Inhibikase Therapeutics, 1 rates it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from IKT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.40, with estimates from -$0.42 to -$0.38 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.41, with estimates from -$0.45 to -$0.37 from 5 analysts.

    What revenue do analysts expect from Inhibikase Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $250000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $400000.

    How many analysts cover IKT?

    10 analysts rate Inhibikase Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.